EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Alpha 3

Ensembl ID : ENSMLUG00000014647
Gene Symbol: ATP1A3
2 Cross references
134 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1

Ensembl ID : ENSMLUG00000010015
Gene Symbol: ATP1B1
2 Cross references
295 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2

Ensembl ID : ENSMLUG00000024537
Gene Symbol: ATP1B2
2 Cross references
274 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3

Ensembl ID : ENSMLUG00000011339
Gene Symbol: ATP1B3
2 Cross references
299 Possible Orthologues:

Atr Serine/threonine Kinase

Ensembl ID : ENSMLUG00000016908
Gene Symbol: ATR
4 Cross references
206 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSMLUG00000013069
Gene Symbol: AXL
2 Cross references
197 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSMLUG00000007544
Gene Symbol: BRAF
2 Cross references
220 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSMLUG00000007491
Gene Symbol: BCL2L1
2 Cross references
286 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSMLUG00000004336
Gene Symbol: BTK
2 Cross references
207 Possible Orthologues:

C-C Motif Chemokine Receptor 1

Ensembl ID : ENSMLUG00000011419
Gene Symbol: CCR1
2 Cross references
299 Possible Orthologues:

C-C Motif Chemokine Receptor 2

Ensembl ID : ENSMLUG00000016718
Gene Symbol: CCR2
2 Cross references
286 Possible Orthologues:

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSMLUG00000029205
Gene Symbol: CCR4
2 Cross references
254 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).